Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | April 23, 2019 | April 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 23, 2019 · Filed April 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 169,935 |
Ending reported balance
After 2019-04-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-23 · Exercise / conversion · Acquired 56,000 · Balance 225,935 Row 2 · 2019-04-23 · Sale · Disposed 56,000 · Balance 169,935 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 113,227 |
Reported balance
After 2019-04-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-23 · Exercise / conversion · Disposed 56,000 · Balance 113,227 F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 1,698 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,698 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 53 |
Reported balance
Holding disclosure · report date 2019-04-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 53 F2: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 23, 2019.
F2: The reporting person disclaims beneficial ownership of all securities held by his spouse.
F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,103 | $62.77 | $132,005.31 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 21 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,619 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,270 | $62.77 | $79,711.55 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 20 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,722 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,400 | $62.76 | $150,624.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 19 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,992 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,231 | $62.76 | $77,251.41 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 18 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,392 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,300 | $62.75 | $144,325.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 17 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,623 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 497 | $62.75 | $31,184.27 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 16 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,923 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,690 | $62.74 | $231,510.60 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 15 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,420 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 303 | $62.74 | $19,008.71 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 14 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,110 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 307 | $62.73 | $19,258.11 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 13 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,413 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.73 | $6,272.50 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 12 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,720 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $62.72 | $25,088.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 11 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,820 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 103 | $62.72 | $6,459.65 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 10 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,220 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.71 | $12,541.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,323 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 103 | $62.70 | $6,458.10 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 8 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,523 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $62.69 | $25,076.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 7 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,626 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $62.68 | $18,804.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,026 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $62.66 | $18,798.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,326 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $62.65 | $18,795.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,626 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $62.64 | $6,264.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,926 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 112 | $62.62 | $7,013.44 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,026 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.95 | $12,590.00 |
DisclosureSEC source: 0001179110-18-001376 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,138 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $62.89 | $12,578.00 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 10 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,975 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $62.87 | $37,722.00 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,175 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 700 | $62.86 | $44,002.00 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 8 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,775 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 600 | $62.86 | $37,713.00 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 7 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,475 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,400 | $62.85 | $87,990.00 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,075 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,198 | $62.85 | $75,288.31 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,475 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,502 | $62.84 | $220,065.68 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,673 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 662 | $62.84 | $41,596.77 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,175 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,506 | $62.83 | $220,281.98 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,837 Read SEC document |
| January 30, 2018 Filed Feb 1, 2018 22:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 945 | $62.83 | $59,369.63 |
DisclosureSEC source: 0001179110-18-001377 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,343 Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 44,000 | $0.00 Strike: $27.03 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 13 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 44,000 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 45,800 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 12 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 45,800 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 28,700 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 11 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 28,700 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 10 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 38,700 shares Expires 2019-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 39,350 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · derivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 39,350 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 196,550 | $49.50 | $9,729,225.00 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 6 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,138 Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 44,000 | $27.03 | $1,189,478.40 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 5 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 45,800 | $22.39 | $1,025,549.02 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 4 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 28,700 | $26.19 | $751,592.73 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 3 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 38,700 | $26.02 | $1,006,780.50 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 2 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 39,350 | $26.70 | $1,050,538.76 |
DisclosureSEC source: 0001179110-17-011662 · edgar.xml · nonDerivative · entry 1 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 44,000 | $0.00 Strike: $27.03 | $0.00 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · derivative · entry 16 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 44,000 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 45,800 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · derivative · entry 15 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 45,800 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 28,700 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · derivative · entry 14 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 28,700 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 38,700 | $0.00 Strike: $26.02 | $0.00 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · derivative · entry 13 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 38,700 shares Expires 2019-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 39,350 | $0.00 Strike: $26.70 | $0.00 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · derivative · entry 12 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 39,350 shares Expires 2018-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 195,700 | $46.00 | $9,002,200.00 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · nonDerivative · entry 9 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,138 Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $46.01 | $13,803.00 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · nonDerivative · entry 8 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,838 Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 21:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $46.02 | $23,010.00 |
DisclosureSEC source: 0001179110-17-008829 · edgar.xml · nonDerivative · entry 7 Fussell Stephen R · CIK 0001327700 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,138 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.